Relapse Prevention With Gepirone ER in Outpatients With Major Depression

  title={Relapse Prevention With Gepirone ER in Outpatients With Major Depression},
  author={Martin Keller and Frank Ruwe and Cecile J. W. Janssens and J. M. Ad Sitsen and Riitta Jokinen and Janusz Janczewski},
  journal={Journal of Clinical Psychopharmacology},
Abstract: To evaluate long-term efficacy and tolerability of the serotonin 5-HT1A receptor agonist, gepirone extended release (ER), a multicenter, randomized, placebo-controlled relapse prevention study was performed in patients with recurrent major depression (DSM-IV criteria). Patients 18 to 70 years, with a primary diagnosis of recurrent major depression (DSM-IV; 296.3) and a screening and baseline HAMD-17 total score ≥20 were eligible. After a 3- to 14-day (dependent on pretrial medication… 

Aripiprazole augmentation in treatment-resistant depression.

Aripiprazole may be effective as an antidepressant augmentation agent in highly treatment resistant patients who had failed a prior trial of another atypical neuroleptic.

The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men.

Gepirone-ER has a pro-sexual effect independent of antidepressant or anxiolytic activity, and improves sexual dysfunction in depressed men.

Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.

Gepirone-ER may have efficacy in the treatment of HSDD among depressed and possibly nondepressed women and does not seem to be purely an antidepressant effect.

Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves

The analysis provided evidence that the prophylactic efficacy of different antidepressant medicines was not constant over time, and a beneficial effect was observed, but the prevention of new episodes after 6 months was questionable.

Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders

This meta-analysis emphasizes the importance of continuation treatment following acute response in depressive disorders, and the robust findings of relapse prevention designs contrast with acute antidepressant efficacy studies, and may be due to enrichment of the patient population.

Depression in adults: drug and physical treatments.

This systematic review presents information relating to the effectiveness and safety of the following interventions: antidepressant drugs (tricyclic antidepressants], selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, reboxetine, or venlafaxine), continuing prescription antidepressant drugs, electroconvulsive therapy, exercise, lithium augmentation, pindolol augmented, St John's Wort.

Impact of Study Design on the Results of Continuation Studies of Antidepressants

The design of continuation studies of antidepressants was associated with the absolute percentage of patients who relapse on both active medication and placebo, as well as estimates of differential relapse risk between antidepressants and placebo.

Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials

Despite evidence of the efficacy of drug treatment compared to placebos or other controls, the findings further underscore the substantial, unresolved morbidity in treated MDD patients and strongly encourage further evaluations of specific, improved individual and combination therapies conducted over longer times.



Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.

Preliminary evidence suggested that gepirone-ER may not be associated with sexual dysfunction and is effective for the short-term treatment of major depressive disorder and is well tolerated.

Long-term drug treatment of unipolar depression.

  • R. Hirschfeld
  • Psychology, Medicine
    International clinical psychopharmacology
  • 1996
There is growing evidence to support the use of a full therapeutic dose of antidepressant in maintenance treatment, and SSRIs are better tolerated than TCAs or MAOIs and display similar efficacy in acute, continuation and maintenance treatment.

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

Serotonin 5-HT1a Receptor Agonists as Antidepressants

For 20 years serotonin 5-HT1A receptor agonists have been evaluated for effectiveness in treating depressive disorders and depressive symptoms occurring in a range of diagnostic categories, including major and minor depression, mixed states of anxiety and depression, and mixed syndromes of depression and alcohol dependence.

Is there a role for 5-HT1A agonists in the treatment of depression?

Serotonin 5-HT1A Agonists

The balance of evidence suggests that the azapirones act as partial agonists postsynaptically, but as full agonists presynaptically in the dorsal raphé, which indicates that buspirone, gepirone and ipsapirone may be more effective in this disorder.

Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1A Receptors

Data indicate that such antidepressant treatments, acting on entirely different primary targets, might alleviate depression by enhancing the tonic activation of forebrain postsynaptic 5-HT1Areceptors.

Electrophysiological Investigation of the Adaptive Response of the 5‐HT System to the Administration of 5‐HT1A Receptor Agonists

It is concluded that the sustained administration of a 5-HT1A agonist results in an enhanced tonic activation of postsynaptic 5- HT1A receptors in the forebrain, which can be presumed that the recovery of the firing activity of 4-HT neurons restores a normal release of endogenous5-HT.